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Previous studies comparing interleukin 4 receptor a (IL-4Ra)
-/- and interleukin 4 (IL-4)
-/- BALB/c mice have
indicated that interleukin 13 (IL-13), whose receptor shares the IL-4Ra subunit with IL-4, plays a protective role
during visceral leishmaniasis. We demonstrate that IL-13
-/- BALB/c mice were less able to control hepatic
growth of Leishmania donovani compared with wild-type mice. This correlated with signiﬁcantly retarded
granuloma maturation in IL-13
-/- mice, defective interferon c (IFN-c) production, and elevated IL-4 and
interleukin 10 (IL-10) levels. L. donovani–infected IL-13
-/- mice also responded poorly to sodium
stibogluconate-mediated chemotherapy compared with wild-type BALB/c mice. Because murine lymphocytes
do not have IL-13 receptors, we examined the ability of macrophage/neutrophil-speciﬁc IL-4Ra
-/- mice to
control primary infection with L. donovani and to respond to chemotherapy. Macrophage/neutrophil-speciﬁc
IL-4Ra
-/- mice were as resistant to leishmaniasis as wild-type mice, and chemotherapy retained its efﬁcacy.
Consequently, in L. donovani infected BALB/c mice, IL-13 promotes hepatic granuloma formation and controls
parasite burdens independently of direct effects on macrophages/neutrophils.
Infection with the intracellular protozoan parasite
Leishmania donovani causes a potentially fatal disease
wherein macrophages of the viscera including the spleen,
liver, and bone marrow become infected, leading to
splenomegaly and hepatomegaly. Resistance to infection
with L.donovaniin the well-characterizedBALB/c mouse
model is associated with an interleukin 1 (IL-1)–driven
type1response,leadingtotheproductionofinterferon-c
(IFN-c) and activation of macrophages [1]. In contrast,
overproduction of interleukin 10 (IL-10) is associated
with disease exacerbation [2, 3]. Control of parasite
growth in the liver is associated with the ability to pro-
duce sterile granulomas [4], a mechanism driven by
T-cell–derived IFN-c [2]. Paradoxically, studies using
interleukin 4 (IL-4)
-/- mice have also demonstrated an
important protective role for this cytokine during pri-
mary infection [4]. Enhanced susceptibility of IL-4
-/-
mice was associated with downregulated type1 responses
[5] and markedly retarded granuloma maturation [4].
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36 d JID 2011:204 (1 July) d McFarlane et alA number of chemotherapeutic options are available to treat
visceral leishmaniasis. Pentavalent antimony (sodium stibo-
gluconate [SSG]) is composed of stibonic and gluconic acids [6]
and has been among the most commonly used antileishmanial
drugs. Several studies have highlighted the importance of T
lymphocytes and associated cytokines in the efﬁcacy of SSG
treatment, indicating that the host cell–mediated immune re-
sponse is an important factor in SSG chemotherapy [2, 5, 7].
Animalstudies havealso demonstrated thatsuccessfultreatment
of visceral leishmaniasis with SSG requires the presence of both
CD4
1 and CD8
1 T cells [7] accompanied by the type 1 cyto-
kines interleukin 12 (IL-12)and IFN-c [2]. Our previous studies
of primary L. donovani infection using IL-4
-/- BALB/c mice
demonstrated that IL-4 plays a protective role and facilitates
successfulchemotherapyby promoting a type 1 response [4, 5].
Additional studies of the primary disease model demonstrated
that interleukin 4 receptor a (IL-4Ra)
-/- BALB/c mice were
signiﬁcantly more susceptible to L. donovani infection than
were IL-4
-/- mice, as measured by liver parasite burdens early
in infection [4]. Because the IL-4 and interleukin 13 (IL-13)
receptors share the IL-4Ra subunit, this clearly suggests a role
for IL-13 in the protective response. Studies using IL-13
-/-
BALB/c mice have been less conclusive, and although IL-13
deﬁciency wasidentiﬁedaspromoting granuloma maturation,
which is correlated with protection, no effect of IL-13 de-
ﬁciency on parasite burdens was observed [8]. Indeed, a study
using mice deﬁcient in the IL-13 decoy receptor IL-13Ra2,
and consequently producing excess functional IL-13, in-
dicated that IL-13 inhibited a type 1 response and promoted
disease [9]. Surprisingly, IL-13 was found to have little effect
on SSG chemotherapy in either study [8, 9], despite the
demonstrated involvement of the related cytokine IL-4 in this
process [5]. However, previous studies on cutaneous leish-
maniasis have demonstrated that although IL-13 can sub-
stitute for IL-4 in its absence, IL-13 can also have independent
properties [10].
Consequently, to more speciﬁcally characterize the role of IL-
13 and its functional targets during infection with L. donovani,
we have used IL-13
-/-, IL-4Ra
-/-, and macrophage/neutrophil-
speciﬁc IL-4Ra
-/- BALB/c mice both during primary infection
with L. donovani and following SSG chemotherapeutic in-
tervention. We demonstrate that IL-13 plays a signiﬁcant role in
controlling hepatic visceral leishmaniasis both during primary
infection and following SSG chemotherapy by promoting a type
1 response and hepatic granuloma maturation. Furthermore,
using macrophage/neutrophil-speciﬁc IL-4Ra
-/- BALB/c mice
[11], we demonstrate that the protective inﬂuence of IL-13 is
independent of these cellular targets. Because murine lympho-
cytesdonotpossessIL-13receptors,theseresultsraiseintriguing
questions regarding the mode of action and cellular targets of
this cytokine. Data reported here suggest that IL-13 functions
through dendritic cells to promote a protective response.
MATERIALS AND METHODS
Animals and Parasites
We used age- and sex-matched, in-house, inbred IL-13
-/- BALB/
c mice (20–25 g, female) and their wild-type counterparts along
with macrophage/neutrophil-speciﬁc IL-4Ra
-/- mice and their
negative littermates [11]. We intercrossed IL-4Ra
lox/lox BALB/c
[11] mice with BALB/c mice expressing Cre recombinase under
the control of the LysM promoter [12] and then further
crossed with IL-4Ra BALB/c mice [13] to generate hemizygous
LysM
creIL-4Ra
-/lox mice. Polymerase chain reaction genotyping
was used to identify LysM
creIL-4Ra
-/lox mice. LysM
cre-negative
IL-4Ra
-/lox BALB/c mice were used as wild-type equivalents.
Commercially obtained golden Syrian hamsters (Mesocricetus
auratus) were used for maintenance of L. donovani strains
(Harlan Olac). L. donovani strains 200016 and LV82 were used
in our study [14]. Mice were infected on day 0 by intravenous
injection (tail vein, no anaesthetic) with 1–2 3 10
7 L. donovani
amastigotes [15]. Animal experiments were performed after
institutional ethical review and in accordance with UK Home
Ofﬁce regulations.
In Vivo Studies
To compare the course of infection in cytokine deﬁcient mice
and their wild-type counterparts (n 5 4 treatment), we infected
mice with L. donovani and killed them on different days post-
infection. In drug studies, infected mice were treated in-
travenously on days 14 and 15 with phosphate-buffered saline
(controls) or SSG solution (Glaxo-Wellcome, equivalent to a ﬁ-
nal dose of 111 mg Sb
v/kg), and we determined parasite burdens
in control and drug-treated animals at day 40 postinfection.
To determine parasite burdens in the spleen and liver, im-
pression smears were prepared on an individual glass micro-
scope slide for each mouse at experiment termination. We
prepared bone marrow smears by exposing the mouse femur,
cutting behind the kneecap, and inserting a needle into the bone
to retrieve the bone marrow. We smeared each bone marrow
sample onto the end of a slide using the needle. We ﬁxed the
slides in methanol for 2 minutes, stained them with a 10%
Giemsa solution (BDH, VWR InternationalLtd) for 20 minutes,
washed them in tap water, and allowed them to dry. We de-
termined the number of parasites per 1000 host nuclei for each
sample at x1000 magniﬁcation.
Generation and Stimulation of Bone Marrow–Derived Dendritic
Cells
We obtained bone marrow–derived dendritic cells from BALB/c
mice (aged 10 wk). We ﬂushed the femurs with 5 mL of Roswell
Park Memorial Institute 1640 medium (RPMI 1640), washed
the cellsuspension,adjustedthe bonemarrowcellconcentration
to 5 x10
5 cells/mL, and cultured the cells in 6-well plates
(Corning Costar) at 37C and 5% CO2 in RPMI 1640, 10% vol/
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1% vol/vol 2 mM L-glutamine solution, 1% vol/vol 100 IU/mL
penicillin, 100 mg/mL streptomycin (PAA Laboratories,
GmbH), and 10% culture supernatant from X63 myeloma cells
transfected with mouse GM-CSF cDNA. We added fresh me-
dium to the cell cultures every 3 days, generating many CD11c
1
dendritic cells largely free from granulocyte and monocyte
contamination. We harvested thecells onday10,seeded them at
5 310
4 cells per well in 96-well tissue culture plates, and treated
them with 100 ng/mL recombinant (r)IL-13 (R&D Systems) or
100 ng/mL lipopolysaccharide (LPS). The cells were either
preincubatedovernightwithrIL-13beforebeingstimulatedwith
LPS for a further 48 hours or incubated with rIL-13 and LPS
together for 72 hours. We froze the supernatants at 220C
before we measured IL-12p40 production by ELISA.
Cytokine Production
We used enzyme-linked immunosorbent assay (ELISA) to
determine IL-4, IL-10, IL-12p40, IL-13, and IFN-c levels in the
sera of L. donovani–infected mice, as previously described [5].
Histology
At termination, we removed sections of liver and ﬁxed them in
neutral-buffered formalin, then processed and stained them
with Haematoxylin and Eosin (Fisher Scientiﬁc). We scored
granulomas as infected Kupffer cells (parasitized macrophages),
immature (developing granuloma consisting of CD4
1 and
CD8
1 T cells and monocytes surrounding infected Kupffer
cells), mature (more developed than immature granulomas), or
sterile (parasite-free granuloma). Granulomas were scored as
previously described in a study by Murray [16].
Statistical Analysis of Data
We analyzed parasite data from in vivo experiments using
a 1-way analysis of variance (ANOVA, using log10-transformed
parasite burden for the liver data). We then analyzed differences
between treatments using a Fisher protected least signiﬁcant
difference (PLSD) test with the Statview version 5.0.1 software
package. We analyzed cytokine, granuloma, and ﬂow cytometry
data using an unpaired t test.
RESULTS
Liver Parasite Burdens Are Increased and Granuloma Formation
Inhibited in IL-13
-/- BALB/c Mice Infected With L. donovani
Parasite burdens in the livers of wild-type and IL-13
-/- BALB/c
mice infected intraveneously with 1–2 3 10
7 L. donovani
amastigoteswere enumeratedatdays14and35postinfection.At
day 14 postinfection, liver parasite burdens were similar in both
wild-type and IL-13
-/- BALB/c mice (Figure 1A). Whereas par-
asite burdens in the livers of wild-type mice had declined by
day 35 postinfection, they did not decline over this period in
IL-13
-/- BALB/c mice, and we found them to be signiﬁcantly
higher (P , .001) in IL-13
-/- than in wild-type mice at this time
(Figure1A).Parasitenumberswerealsofoundtobesigniﬁcantly
greater in the spleens and bone marrow of L. donovani–infected
IL-13
-/- compared with those found in wild-type BALB/c mice
(Figures 1B and C).
We also assessed granuloma maturation in livers from wild-
type and IL-13
-/- mice over this period (Figures 2A and 2B). We
scored granulomas as described previously [16]: infected
Kupffer cells (parasitized macrophages), immature granuloma
(consisting of T cells and monocytes surrounding infected
Kupffer cells), mature (developed), or sterile (parasite-free)
granuloma. IL-13
-/- BALB/c mice showed normal early in-
ﬂammatory responses, with the formation of immature
Figure 1. The L. donovani liver (A), spleen (B), and bone marrow (C)
parasite burdens at days 14 and 35 postinfection following intravenous
infection with 1–2 3 10
7 amastigotes. The data are means 6 standard
errors for individual mice (n 5 4) and are representative of 1 of
4 independent experiments.
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postinfection (Figure 2A). Whereas approximately 60% of
the inﬂammatory foci had progressed to mature or sterile
granulomas in wild-type mice at day 35 postinfection
(Figures 2B–C), granulomas failed to mature in IL-13
-/- mice
(Figures 2B–D) and the histological proﬁle was similar to that of
day 14. Because the overall granulomatous response at day 35 is
indicative of a good healing response [16], which is reﬂected by
the reduction in parasite burdens in wild-type mice, these
data suggest that host-protective granulomatous responses were
inhibited in IL-13
-/- mice.
Serum Cytokine Levels Correspond to a Deficient Type-1
Response in L. donovani Infected IL-13
-/- Compared With
Wild-Type BALB/c Mice
IFN-c is important in controlling granuloma maturation;
Murray et al have previously shown that IFN-c-deﬁcient mice are
unable to control parasite burdens and granuloma formation [2].
We found serum IFN-c levels at day 35 postinfection to be sig-
niﬁcantly greater (P , .0001) in L. donovani–infected wild-type
mice compared with levels in IL-13
-/- BALB/c mice (Figure 3A).
We also found L. donovani to induce high serum IL-13 levels in L.
donovani–infected wild-type mice (Figure 3B). Conversely, both
IL-4 and IL-10 serum levels were greater in IL-13
-/- mice
compared with levels in wild-type mice (Figure 3C and D re-
spectively). Together these results show a positive association of
IFN-c and IL-13 production with granuloma maturation and
a negative association with IL-4 and IL-10 levels. Consistent with
these observations, IL-12 serum levels peaked earlier in infection
in wild-type mice compared with levels in IL-13
-/- mice (Figure
3E). As well as systemic cytokine levels, the percentage of IFN-
c-secreting CD4
1 T cells and CD8
1 T cells was signiﬁcantly
Figure 3. Mean serum IFN-c (A), IL-13 (B), IL-10 (C), and IL-4 (D)
levels 6 standard errors in wild-type and IL-13
-/- BALB/c mice (n 5 4) at
day 35, and IL-12 p40/70 (E) at days 14 and 35 postinfection with
L. donovani as measured in individual serum samples by enzyme-linked
immunosorbent assay. Representative data from 4 independent experi-
ments are shown. No measurable cytokine levels were observed in sera
from uninfected wild-type and IL-13
-/-mice. Analysis of intracellular IFN-c
expression (F) was performed on day 35 postinfection on splenocytes
stimulated in the presence of 50 ng/mL phorbol myristate acetate (Sigma-
Aldrich) and 500 ng/mL of ionomycin (Sigma-Aldrich) for 4 hours, with the
addition of Brefeldin A during the last 2 hours as previously described.
The antimouse antibody PerCP-labeled anti-CD4
1, activated protein
C–labeled anti-CD8
1, peridinin chlorophyll protein–labeled, and acti-
vated protein C–labeled IgG isotype controls were used to stain the cell
surfaces, and the protein E–labeled anti-mouse IFN-c and protein
E–labeled IgG isotype control were used for intracellular staining. All
antibodies were obtained from BD Biosciences. Cells were analyzed with
the FACSCanto. The FACsDiva software was used to analyze results.
Representative of 2 separate experiments. *P ,.05, **P ,.01 wild-type
versus IL-13
-/-.N D5 not detected.
Figure 2. Granuloma maturation in L. donovani–infected wild-type and
IL-13
-/- mice at days 14 (A) and 35 (B) postinfection. The data are means
6 standard errors for 1 of 4 independent experiments. *P , .05 and
**P , .01 wild-type versus IL-13
-/-. Photomicrographs showing the
hepatic granuloma response in two L. donovani–infected mice, wild-type
(C) and IL-13
-/- (D), at day 35 postinfection. Wild-type mice show well-
developed mature granulomas (arrows) surrounding a core of infected
Kupffer cells, whereas IL-13
-/- mice show abrogated granuloma
development characterized by the presence of immature granulomas
and amastigotes within the cytoplasm of Kupffer cells at day 35
postinfection (arrows). Magnification x400.
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-/- mice
(Figure 3F; wild-type mice, 7.9 6 0.265% CD4
1 IFN-c
1 T cells
and 15.5 6 0.354% CD8
1 IFN-c
1 T cells; IL-13
-/- mice, 6.1
6 0.24% CD4
1 IFN-c
1 T cells and 12.0 6 0.841% CD8
1 IFN-
c
1 T cells).
Sodium Stibogluconate Drug Treatment Was Ineffective in
IL-13
-/- BALB/c Mice and Granulomas Failed to Mature
We treated L. donovani–infected wild-type and IL-13
-/- BALB/c
micewithSSG(111mgSb
v/Kg)ondays14and15postinfection,
and we compared parasite burdens with those of non–drug-
treated control mice at day 40 postinfection. We calculated SSG
parasite suppression bycomparing each experimental value with
the mean control value. As expected, SSG drug treatment was
successful in wild-type animals, resulting in 61% suppression of
parasite numbers in the liver (Figure 4A). Interestingly, SSG
drug treatment was ineffective in IL-13
-/- mice, as parasite
burdens at day 40 postinfection were similar to control values.
We assessed granuloma maturation in livers from control and
drug-treated mice of both wild-type and IL-13
-/- BALB/c strains
as we described previously. As expected, wild-type mice
demonstrated a signiﬁcant amount of granuloma maturation
whereby there were few infected Kupffer cells remaining without
associated inﬂammation, although immature and, to a lesser
extent, mature granulomas were predominant; and some sterile
granulomas were also evident (Figure 4B). In drug-treated wild-
type mice, however, there was a signiﬁcant increase in mature
but particularly sterile granulomas compared with granulomas
in non–drug-treated animals (P , .001), whereas levels of in-
fected Kupffer cells and immature granulomas were reduced
greatly (Figure 4C). In non–drug-treated IL-13
-/- BALB/c mice,
granulomas failed to mature as infected Kupffer cells were dom-
inant, and there were few mature and sterile granulomas (Figure
4B). Furthermore, SSG treatment did not promote any signiﬁcant
granuloma maturation in IL-13
-/-BALB/c mice (Figure 4C).
The L. donovani Protective Influences of IL-13 Are Independent
of Macrophage/Neutrophil Involvement
Murine lymphocytes are not responsive to IL-13, suggestingthat
the effects of IL-13 are indirect. Previous studies suggest that in
Listeria monocytogenes infection, IL-13 drives IL-12 production
by monocytes and a protective type 1 response against the in-
fection [17, 18]. To test the possible role of IL-13–responsive
macrophages in the protective responses against L. donovani,w e
used recently established macrophage/neutrophil-speciﬁc
IL-4Ra
-/- BALB/c mice [11] for comparative Ld o n o v a n iin-
fection studies.
Primary infection of macrophage/neutrophil-speciﬁc IL-
4Ra
-/- mice (LysMcreIL-4Ra
-/lox) and their control littermates
(IL-4Ra
-/lox) with L. donovani resulted in similar liver parasite
burdens (Figure5A)andgranulomamaturation(Figures5Band
5C). As previously published, global IL-4Ra
-/- BALB/c mice
were more susceptible to infection than wild-type mice and have
retarded granuloma development [4] with a histological phe-
notype similar to IL-13
-/- animals (results not shown).
SSG drug-induced suppression of parasite burdens in
the liver was equivalent in control (59%) and macrophage/
neutrophil-speciﬁc IL-4Ra
-/- (55%) mice at day 40 post-
infection (Figure 6A), indicating that treatment was successful
in both mouse strains. In agreement, compared with non-
drug-treated mice (Figure 6B), both drug-treated control
mice and macrophage/neutrophil-speciﬁc IL-4Ra
-/- mice
(Figure 6C) showed a signiﬁcant increase (P , .01 and P , .001
respectively) in sterile granulomas (Figure 6B).
IL-13 Primes Dendritic Cells for IL-12 Production
Previous studies have demonstrated that IL-4 can prime den-
dritic cells for IL-12 production and a protective immune re-
sponse against Leishmania major [19, 20]. Because IL-13 also
signals through the IL-4Ra chain and has similar functions to
IL-4, we tested the possibility that IL-13 was also able to instruct
dendritic cells for IL-12 production. We preincubated dendritic
cells with rIL-13 either prior to or at the same time as LPS
Figure 4. Sodium stibogluconate–mediated suppression of parasite
burdens in the liver and granuloma maturation in IL-13
-/- and wild-type
BALB/c mice infected with L. donovani. The mean suppression
(6 standard error [SE]) of parasite burdens induced by treatment with
111 mg Sb
v/kg sodium stibogluconate (SSG) at days 14 and 15
postinfection in the livers of wild-type and IL-13
-/- mice was assessed at
day 40 postinfection (A). Parasite suppression was measured by
comparing each experimental value with the mean control value (NS 5
no suppression). Granuloma maturation in non–drug-treated (B) and drug-
treated (C) L. donovani–infected wild-type and IL-13
-/- mice at day
40 postinfection was also measured. Paraffin-embedded liver sections
from wild-type and IL-13
-/- mice (n 5 4) were stained with haematoxylin
and eosin, and granuloma formation per 100 microscopic fields was
determined. The data are means (6SE) for 1 of 2 independent ex-
periments. **P ,.01 wild-type versus IL-13
-/-.
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duction by ELISA. Preincubation of dendritic cells with rIL-13
induced signiﬁcantly increased levels of IL-12 production
compared with levels from LPS stimulation alone (P , .0021,
Figure 7). Indeed, preincubation of dendritic cells with rIL-13
was necessary to induce upregulation of IL-12 production fol-
lowing LPS stimulation because incubation of dendritic cells
with rIL-13 and LPS together did not lead to signiﬁcantly in-
creased IL-12 levels compared with levels produced from LPS
stimulation alone (P , .0625, Figure 7).
DISCUSSION
Our previous studies identiﬁed a protective role for IL-4 and
IL-4Ra signaling during L. donovani infection [4, 5]. Further-
more, the increased susceptibility to L. donovani of IL-4Ra
-/-
micecomparedwiththatofIL-4
-/- BALB/cmice, as measuredby
hepatic parasite burdens [4], suggested a protective role for
IL-13 also, because activities of both IL-4 and IL-13 are de-
pendent on the expression of IL-4Ra. Whereas serum IFN-c
levels were similar in wild-type and IL-4
-/- L. donovani–infected
BALB/c mice, we measured no detectable IFN-c in IL-4Ra
-/-
animals, which suggests that IL-13 alone or IL-13 and IL-4 to-
gether are essential for optimal development of type 1 responses
andimmunity againstthis parasite [4].Thisstudy conﬁrmedthe
suggestion by demonstrating that IL-13 promotes a protective
response against visceral leishmaniasis, as parasite burdens were
signiﬁcantly enhanced and granuloma maturation was signiﬁ-
cantly inhibited in IL-13
-/- BALB/c mice compared with those in
wild-type mice. Concomitantly, type 1 responses, as measured
by IFN-c production, were signiﬁcantly inhibited; type 2 re-
sponses, as measured by IL-4 and IL-10 levels, were signiﬁcantly
enhanced in L. donovani–infected IL-13
-/- BALB/c mice com-
paredwithresponsesintheirwild-typecounterparts.Thiswould
suggestthat IL-13 has a major role in regulating type 1 responses
and resistance to L. donovani.
The Th2-potentiating role normally associated with IL-13
seems intuitively at odds with our results. However, some
studies have demonstrated that IL-4 and IL-13 indirectly drive
protective type 1 responses. For example, IL-13 has previously
been shown to prime monocytes for IL-12 production [17] and
drive a protective type 1 response during listeriosis [18]. Fur-
thermore, a recent study on L. donovani that failed to demon-
strate a protective role, as measured by hepatic parasite burdens,
for IL-13 during L. donovani primary infection or following
chemotherapy infection demonstrated that this cytokine pro-
moted granuloma formation and IFN-c production during
primary infection [8]. Thus, this study, like our own, clearly
identiﬁed a switch toward a type 1 immune response bias.
Figure 6. The mean suppression (6standard error) of liver parasite
burdens and granuloma induction in the livers of wild-type (IL-4Ra
-/lox)
and macrophage/neutrophil-specific IL-4Ra
-/- (LysM
creIL-4Ra
-/lox) mice at
day 40 postinfection. These are representative data from 2 independent
experiments: liver parasite burdens (A), and granuloma maturation in
control (B) and drug-treated (C) L. donovani–infected IL-4Ra
-/lox and
LysM
creIL-4Ra
-/lox mice at day 40 postinfection. Mice were treated with
phosphate-buffered saline (controls) or 111mg Sb
v/kg sodium stibogluc-
onate at days 14 and 15 postinfection. A significant increase in sterile
granulomas was observed between control and drug-treated mice with
P , .01 and P , .001 for IL-4Ra
-/lox and LysM
creIL-4Ra
-/lox mice,
respectively. *P , .05 drug-treated wild-type (IL-4Ra
-/lox) versus drug-
treated macrophage/neutrophil-specific IL-4Ra
-/- (LysM
creIL-4Ra
-/lox).
Figure 5. Liver parasite burdens in wild-type (IL-4Ra
-/lox) and
macrophage/neutrophil-specific IL-4Ra
-/- BALB/c (LysM
creIL-4Ra
-/lox) mice
at day 40 postinfection with 1–2 3 10
7 L. donovani amastigotes. Part A
shows representative data from 3 independent experiments. Parts B and
C are light micrographs from an IL-4Ra
-/lox mouse and a LysM
creIL-4Ra
-/lox
mouse, respectively, at day 40 postinfection; they show mature
granulomas (arrows) consisting of well-developed mononuclear cell
mantles (magnification 400x).
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asite strains used in the separate laboratories. However, we had
similar resultsinourstudies with 3separate strains,including an
SSG-resistant strain [15].
Previous studiesonL.major infection havealsodemonstrated
a protective role for IL-13, as IL-4Ra
-/- BALB/c mice, unlike
IL-4
-/- mice, were unable to avoid disease dissemination and
visceralization [13]. Because murine lymphocytes do not have
receptors for IL-13,other cellpopulations must be instructedfor
a protective role by this cytokine in the absence of IL-4. Indeed,
a recent study using CD4
1 T-cell–speciﬁc IL-4Ra
-/- mice has
demonstrated that these mice, unlike global IL-4Ra
-/- mice, are
as resistant to L. major as C57BL/6 animals. Consequently,
Radwanska et al concluded that IL-4/IL-13 responsive non-CD4
T cells induce protection against L. major in the absence of
CD4
1 T cells responding to IL-4 [19]. Because Flesch et al had
previously shown that IL-13 primes monocytes for IL-12 pro-
duction [17] and drives a protective type 1 response during
listeriosis [18], we examined L. donovani disease progression in
macrophage/neutrophil-speciﬁc IL-4Ra
-/- BALB/c mice. We
found macrophage/neutrophil-speciﬁc IL-4Ra
-/- mice to be no
more susceptible to infection with L. donovani than their wild-
type littermates were. Over a number of experiments we noted
anindication,althoughgenerallynotsigniﬁcant,thatgranuloma
maturation was more precocious in macrophage/neutrophil-
speciﬁc IL-4Ra
-/- L. donovani–infected BALB/c mice especially
followingchemotherapy. Thisclearly suggeststhattheprotective
role we have demonstrated for IL-13 during L. donovani in-
fection is not due to the activity of this cytokine, or indeed IL-4,
on macrophage/neutrophil populations. Ho ¨lscher et al found
that L. major disease progression was inhibited in macrophage/
neutrophil-speciﬁc IL-4Ra
-/- BALB/c mice compared with
progression in wild-type animals; their study indicated that
IL-13/IL-4 functioned to enhance disease progression by the
induction of alternative macrophage activation [21]. Our
results in this study neither rule out nor conﬁrm whether al-
ternative macrophage activation contributes to susceptibility to
L. donovani. However, alternative macrophage activation could
explain the transiently elevated parasite burdens and impaired
granuloma maturation in the presence of excess IL-13 in
IL-13Ra2
-/- L. donovani–infected mice [9]. Consequently, the
protective effects, as opposed to disease-exacerbatory effects, of
IL-4/IL-13 during both L. major and L. donovani infections are
due to cell populations other than macrophages or neutrophils.
Dendritic cells, for example, would be strong candidates because
they play pivotal roles in granuloma formation [22], and an
elegant study has previously shown IL-4 to induce dendritic cell
IL-12 production and to generate a T-helper 1 (Th1) response
and protection against L. major [20]. Furthermore, Ghosh et al
found that IL-4–matured bone marrow–derived dendritic
cell–based immunotherapy signiﬁcantly enhances chemother-
apy against murine visceral leishmaniasis [23]. They also found
that IL-13 can induce dendritic cell IL-12 production in vitro
when used to prime dendritic cells prior to LPS stimulation. The
ability of IL-13 to inﬂuence dendritic cells in this way may
play an important role in enhancing granuloma formation and
reducing parasite burdens during L. donovani infection.
In addition to being more susceptible than wild-type mice to
primary infection with L. donovani,I L - 1 3
-/- animals responded
less well to SSG chemotherapy, as in fact did IL-4
-/- BALB/c mice
in a previous study [5]. This would again suggest that IL-4 and
IL-13 are playing similar protective roles during L. donovani
infection. However, as serum IL-4 levels in L. donovani–infected
IL-13
-/- BALB/c mice were signiﬁcantly higher than levels in
wild-type animals,this wouldsuggestthatIL-13 couldbeplaying
a role independently of IL-4. Using IL-4
-/- mice, studies of
asthma [24], schistosomes [25], and Nippostrongulas braziliensis
[26], as well as L. major [10] have demonstrated that IL-13,
which has the ability to substitute in part for IL-4, has in-
dependent properties or plays a more signiﬁcant role than IL-4
in various functions. These functions include worm expulsion of
N. braziliensis [26], effector activity in asthma [24, 27], and
hepatic ﬁbrosis and granuloma formation in the pathology as-
sociated with schistosomiasis [25]. Paradoxically,although IL-13
appears to be the main mediator of a type 2 immune response,
our data suggest that this cytokine is also crucial in generating
the granuloma-inducing type 1 immune response associated
with protection against L. donovani. Nevertheless, in a previous
coinfection study [28], schistosome egg granulomas were found
to provide safe havens for the multiplication of L. donovani
amastigotes, even in the presence of functional anti–L. donovani
Th1 responses.
Figure 7. Effect of recombinant interleukin 13 and lipopolysaccharide
stimulation on interleukin 12 production by dendritic cells. Dendritic cells
were either (a) incubated for 72 hours with lipopolysaccharide (LPS) alone
(100 ng/mL), recombinant interleukin 13 (rIL-13) alone (100 ng/mL), or LPS
and rIL-13 together, or (b) preincubated with rIL-13 overnight and then
stimulated with LPS for a further 48 hours. Supernatants were frozen
at 220C before analysis for IL-12p40 by enzyme-linked immunosorbent
assay. Preincubating with rIL-13 prior to LPS stimulation induced
a significant increase in IL-12p40 production by dendritic cells compared
with LPS stimulation alone (P ,.0021) or incubation with rIL-13 and LPS
together (P ,.0001). pi 5 preincubated.
42 d JID 2011:204 (1 July) d McFarlane et alTogether, our results demonstrate that IL-13 overall plays
a beneﬁcial role during L. donovani infection independent of
a direct role for lymphocytes, macrophages, or neutrophils and
is important in the generation of cell-mediated immunity.
Preliminary evidence implicates the dendritic cell as a potential
target for the IL-13 dependent protective response against
L. donovani. However, ﬁnal conﬁrmation will be dependent on
the generation of CD11c-speciﬁc IL-4Ra
-/- mice.
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